Portola Pharma (PTLA) Tops Q4 EPS by 5c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($1.41), $0.05 better than the analyst estimate of ($1.46). Collaboration and License revenue for the quarter came in at $9.8 million versus the consensus estimate of $6.2 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Prenetics Global (PRE) Tops Q2 EPS by 18c